KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Minority Interest (2016 - 2018)

Historic Minority Interest for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q3 2018 value amounting to $28.4 million.

  • Vertex Pharmaceuticals' Minority Interest rose 13313.06% to $28.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was $28.4 million, marking a year-over-year increase of 13313.06%. This contributed to the annual value of $13.7 million for FY2017, which is 9244.15% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Minority Interest stood at $28.4 million for Q3 2018, which was up 13313.06% from $28.7 million recorded in Q2 2018.
  • Vertex Pharmaceuticals' 5-year Minority Interest high stood at $196.0 million for Q2 2017, and its period low was $12.2 million during Q3 2017.
  • Moreover, its 5-year median value for Minority Interest was $153.5 million (2015), whereas its average is $106.9 million.
  • Its Minority Interest has fluctuated over the past 5 years, first surged by 65486.98% in 2016, then crashed by 9348.64% in 2017.
  • Vertex Pharmaceuticals' Minority Interest (Quarter) stood at $21.2 million in 2014, then surged by 625.6% to $153.7 million in 2015, then grew by 18.19% to $181.6 million in 2016, then crashed by 92.44% to $13.7 million in 2017, then soared by 106.64% to $28.4 million in 2018.
  • Its last three reported values are $28.4 million in Q3 2018, $28.7 million for Q2 2018, and $29.8 million during Q1 2018.